{"schema_version":"secwatch.filing_event.v1","accession":"0001356576-23-000008","form_type":"8-K","ticker":"SUPN","cik":"0001356576","company_name":"SUPERNUS PHARMACEUTICALS, INC.","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.598386+00:00","generated_at":"2026-06-18T21:32:52.754253+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Supernus Q4/FY2022: total rev $667.2M (+15% YoY); Qelbree sales $61.3M; FY2023 rev guidance $580-620M","bullets":["Full year 2022 total revenues $667.2M (+15% YoY); Q4 net product sales $163.8M (+6% vs Q4 2021).","Qelbree net sales $61.3M in FY2022 (vs $9.9M in FY2021); GOCOVRI $104.4M (+19% vs FY2021).","GAAP diluted EPS $1.04 for FY2022 (Q4: $0.43); non-GAAP operating earnings $148.8M.","FY2023 revenue guidance $580-620M (excl. Trokendi XR), ~30% growth; non-GAAP op earnings $65-95M.","Cash $555.2M at Dec 2022; $150M credit line from UBS; SPN-830 FDA meeting April 2023; SPN-820 Phase II ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001356576-23-000008","json":"https://secwatch.observer/filing/0001356576-23-000008.json","markdown":"https://secwatch.observer/filing/0001356576-23-000008.md","text":"https://secwatch.observer/filing/0001356576-23-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356576/000135657623000008/0001356576-23-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356576/000135657623000008/supn-20230228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T21:32:52.754253+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"95e75a8971c50300a9af32a3a082a89cdec0fdf5","claim":"SUPERNUS PHARMACEUTICALS, INC. reported the full year ended December 31, 2022 results: revenue $667.2 million. Guidance initiated.","evidence_excerpt":"Full Year 2022 total revenues of $667.2 million, a 15% increase compared to full year 2021","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1356576/000135657623000008/0001356576-23-000008-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2022"},{"label":"Revenue","value":"$667.2 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"dca78e680e69903847a730266fdfb88b6da7ece1","claim":"SUPERNUS PHARMACEUTICALS, INC. updated its the fourth quarter ended December 31, 2022 guidance (initiated).","evidence_excerpt":"On February 28, 2023, Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) issued a press release regarding its financial results for the fourth quarter and full year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1356576/000135657623000008/0001356576-23-000008-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}